The FDA has approved Tryngolza (olezarsen) as the first therapy specifically designed to lower triglycerides and reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia, according to the drug’s manufacturer, Ionis Pharmaceuticals.
The drug, an apolipoprotein C-III inhibitor, is given once a month via an autoinjector. It comes in two doses: 50 mg and 80 mg.
Severe hypertriglyceridemia — or sHTG — is a condition where triglyceride levels stay dangerously high, often at extremely high levels. That level puts patients at risk for sudden, severe attacks of pancreatitis.
Related: Medical Malpractice Law Firm: Protecting Victims of Negligence and Upholding Justice
How the drug works
Olezarsen targets apolipoprotein C-III, a protein that normally slows down the breakdown of triglycerides. By blocking that protein, it helps clear fats from the blood more efficiently.
The FDA had already granted it orphan drug status in February 2024 for familial chylomicronemia syndrome, a rare and extreme form of that condition. That designation sped up development and review.
The approval covers sHTG broadly — not just the familial form.
Related: Aesthetic Insure – Best Cosmetic Isurance Packages
Clinical trial results
The therapy demonstrated sustained triglyceride control at 12 months.
Side effects and real-world considerations
The most common adverse events were injection site reactions and increases in liver enzymes. The manufacturer says it is meant to be used alongside diet, not as a standalone fix.
Emily Draud, interim executive director of the National Pancreas Foundation, said in the release that the therapy offers “hope” for a community that has had few options. She emphasized the constant fear of unpredictable pancreatitis attacks.
Related: From Struggle to Strength: The Impact of Residential Rehab
How these trial results will hold up in everyday practice remains uncertain. The studies were tightly controlled, and real-world patient populations often include people with multiple health conditions who might not respond the same way. Long-term safety data beyond 12 months aren’t available yet.
What comes next
The company plans to make it available through specialty pharmacies. The autoinjector design is meant to make monthly self-administration easier for patients who have struggled with daily pills or lifestyle changes alone.
Doctors now have a new tool for a condition that, until recently, had no approved therapy aimed directly at preventing pancreatitis. Whether it will be widely adopted depends on pricing, insurance coverage, and how well patients tolerate it over time.